Abstracts tagged "SLE"

Abstract Number: 708 • 2017 ACR/ARHP Annual Meeting
Anti-RNP/Sm Antibodies Plus Lupus Anticoagulant As Risk Factor for Thrombosis in Patients with Systemic Lupus Erythematosus
Mari Carmen Zamora-Medina¹, Andrea Hinojosa-Azaola², Carlos Núñez-Álvarez³ and Juanita Romero-Diaz⁴, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutricion S.Z., Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico
Background/Purpose: In a previous study, we identify a potential role of anti-RNP/Sm in combination with LA as risk factor for thrombosis. We aimed to validate…
Abstract Number: 1611 • 2017 ACR/ARHP Annual Meeting
Increased Body Mass Index May Not be a Risk Factor for the Development of Lupus Nephritis
Yu Pei Chock¹, Abhijeet Danve¹, Wei Fu² and Michelle Petri³, ¹Rheumatology, Yale University, New Haven, CT, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Studies have indicated that increased body mass index (BMI) is a risk factor for development of Chronic Kidney Disease (CKD). Obesity is a low…
Abstract Number: 1838 • 2017 ACR/ARHP Annual Meeting
Estimating Duration of Response in Systemic Lupus Erythematosus (SLE) Trials
Mimi Kim¹, Joan T. Merrill², Kenneth C. Kalunian³, Leslie Hanrahan⁴ and Peter M. Izmirly⁵, ¹Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ⁴Lupus Foundation of America, Washington DC, DC, ⁵Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: The primary endpoint in SLE trials is usually response to therapy at a landmark visit. However, during a trial, patients may alternate between response…
Abstract Number: 2632 • 2017 ACR/ARHP Annual Meeting
The Southern California Lupus Registry: I. Baseline Characteristics of Patients with Systemic Lupus Erythematosus in an Uncharted Territory
Joshua Liu¹, Kathleen Teves², Van La², Arlene Bravo³, Sheila Lezcano⁴, Talha Khawar⁴, Ebrahim Sadeghi⁴, Cong-Bin Wang⁵, Karina Torralba⁶, Howard Yang⁵ and Vaneet K. Sandhu⁷, ¹Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA, ²Internal Medicine, University of California, Riverside, Riverside, CA, ³Internal Medicine, Loma Linda University, Loma Linda, CA, ⁴Rheumatology, Loma Linda University Medical Center, Loma Linda, CA, ⁵Loma Linda University Medical Center, Loma Linda, CA, ⁶Internal Medicine/Rheumatology, Loma Linda University, Loma Linda, CA, ⁷Division of Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: The Southern California Lupus Registry (SCOLR) is a population-based, longitudinal, multi-ethnic cohort of subjects with SLE directed toward studying health and healthcare disparities in…
Abstract Number: 722 • 2017 ACR/ARHP Annual Meeting
Differential Diagnosis of Autoimmune Diseases, Outlier Detection Plus Subgrouping in Clinical Trials By High Content Autoantibody Profiling
Peter Schulz-Knappe, Petra Budde and Hans-Dieter Zucht, Protagen AG, Dortmund, Germany
Background/Purpose: Early diagnosis as well as initiation of successful treatment are two big challenges in the management of patients with autoimmune diseases (AID). Overlap of…
Abstract Number: 1625 • 2017 ACR/ARHP Annual Meeting
Incidence and Outcomes of Venous Thromboembolism in Hospitalized Patients with Systemic Lupus Erythematosus: Results from Nationwide Inpatient Sample Database 2003-2011
Shweta Kishore¹, Varun Mittal², Shradha Ahuja³ and Vikas Majithia^1,4, ¹Division of Rheumatology, University of Mississippi, Jackson, MS, ²Division of Hematology and Oncology, Albert Einstein Healthcare Network, Philadelphia, PA, ³Division of Hospital Medicine, University of Mississippi, Jackson, MS, ⁴Jackson VA Medical Center and University of Mississippi, Jackson, MS
Background/Purpose: Venous thromboembolism (VTE) is a major cause of mortality and morbidity in hospitalized patients. Hospitalized patients with autoimmune disorders are particularly at risk of…
Abstract Number: 1917 • 2017 ACR/ARHP Annual Meeting
A Novel Type I Interferon Biomarker on B Cell Predicts with Disease Activity in SLE and Can be Measured By Cell Surface Tetherin (CD317)
Yasser M El-Sherbiny^1,2,3, Md Yuzaiful Md Yusof¹, Antonios Psarras¹, Elizabeth M.A. Hensor¹, Kumba Kabba¹, Alaa Mohamed^1,4, Miriam Wittmann⁵, Paul Emery^5,6 and Edward M Vital^1,5,7, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom, ³Clinical Pathology dept., School of Medicine, Mansoura University, Mansoura, Egypt, ⁴Faculty of Medicine, Assiut University, Department of Rheumatology and Rehabilitation, Assiut, Egypt, ⁵NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: SLE is an IFN-I-mediated disease with dysregulated handling of self-nuclear antigens triggering anti-viral immune mechanisms. The level of IFN-I activity appears to stratify for…
Abstract Number: 2633 • 2017 ACR/ARHP Annual Meeting
Patients with Secondary Sjögren’s Syndrome to SLE Are Characterized By Typical Autoantibodies and a Pro-Inflammatory State
Marika Kvarnstrom¹, Guillermo Ruacho², Johanna Gustafsson³, Agneta Zickert⁴, Vilija Oke⁵, Johan Rönnelid⁶, Kerstin Elvin⁷, Iva Gunnarsson⁸ and Elisabet Svenungsson⁸, ¹Unit of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Department of Medicine, Unit of Rheumatology,, Stockholm, Sweden, ³Dep. of Medicine, Karolinska Institutet, Karolinska University Hospital, Unit of rheumatology,, Stockholm, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Department of Medicine, Rheumatology Unit, Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁶Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁷Department of Clinical Immunology and Transfusion Medicine,, 4Unit of Clinical Immunology, Stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose :Sjögren´s syndrome occurs in isolation (primary Sjögren´s syndrome, pSS), but it is also often secondary (sSS) to, and sometimes difficult to delineate from, other…
Abstract Number: 829 • 2017 ACR/ARHP Annual Meeting
Unraveling Race and Social Context in Understanding Disparities in Lupus Mortality in the United States
Titilola Falasinnu¹, Yashaar Chaichian², Latha Palaniappan³ and Julia F Simard⁴, ¹Health Research and Policy, Stanford University, Stanford, CA, ²Medicine, Immunology & Rheumatology Division, Stanford School of Medicine, Stanford, CA, ³Stanford University Medical Center, General Medical Disciplines, Stanford, CA, ⁴Division of Epidemiology, Health Research and Policy Department, Stanford School of Medicine, Stanford, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is a source of significantly decreased life expectancy in the United States. Women and…
Abstract Number: 1628 • 2017 ACR/ARHP Annual Meeting
Atrial Fibrillation/Flutter Hospitalizations Among Patients with SLE and Diabetes Compared to the General U.S. Medicaid Population
Sarah Chen¹, Medha Barbhaiya², Michael A. Fischer³, Hongshu Guan⁴, Candace H. Feldman⁵, Brendan M. Everett⁶ and Karen H. Costenbader⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Brigham & Women's Hospital, Boston, MA, ⁶Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: SLE patients have increased cardiovascular disease (CVD) risk, including higher risk of stroke, compared to age- and sex-matched diabetes mellitus (DM) patients. Although DM…
Abstract Number: 1919 • 2017 ACR/ARHP Annual Meeting
The SLE-Key Test Detects an SLE Serologic Signature That Persists over Time and Is Independent of Disease Activity
Chaim Putterman¹, Michelle Petri², Roberto Caricchio³, Jim C. Oates⁴, Pennina Safer⁵, Keren Jakobi-Brook⁵, Rachel Sorek⁵, Ilana Gluzman⁵, Steve Wallace⁶ and Irun R. Cohen^5,7, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ²Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ³Temple Lupus Clinic, Temple University, Philadelphia, PA, USA, Philadelphia, PA, ⁴Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁵ImmunArray Ltd., Rehovot, Israel, Rehovot, Israel, ⁶ImmunArray Inc., VA, USA, Richmond, VA, ⁷Weizmann Institute of Science, Rehovot, Israel, Rehovot, Israel
Background/Purpose: We have developed the iCHIP1,2 to profile repertoires of serum autoantibodies. The first iCHIP application was the SLE-key RuleOut test3,4 , to rule out…
Abstract Number: 2637 • 2017 ACR/ARHP Annual Meeting
A Novel Regulatory Antigen Presenting B Cell and Memory Regulatory T Cell Subsets Are Enriched during the Quiescent Phase of Childhood Onset Systemic Lupus Erythematosus
Joo Guan Yeo^1,2, Thaschawee Arkachaisri^1,3, Lena Das¹, Justin Hung Tiong Tan¹, Jing Yao Leong², Yun June Angela Tan⁴, Liyun Lai⁵, Loshinidevi D/O Thana Bathi², Phyllis Chen², Seck Choon Elene Lee¹, Yun Xin Book¹ and Salvatore Albani^5,6, ¹Rheumatology and Immunology Service, KK Women's and Children's Hospital, Singapore, Singapore, ²Singhealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, ³Duke-NUS Medical School, Singapore, Singapore, ⁴Department of Paediatric Anaesthesia, KK Women's and Children's Hospital, Singapore, Singapore, ⁵SingHealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, ⁶KK Women's and Children's Hospital, Singapore, Singapore
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-factorial disease and the conventional oligo-dimensional investigative approach involving one or a few cell subsets at a time…
Abstract Number: 833 • 2017 ACR/ARHP Annual Meeting
Chronic Cutaneous Lupus Erythematosus Patients Have a Breakdown in Autoreactive VH4.34 Antibody Tolerance While Maintaining Tolerance to dsDNA and Chromatin
Scott Jenks¹, Regina Bugrovsky¹, Xiaoqian Wang^1,2, Aisha Hill³, Chungwen Wei⁴, S. Sam Lim⁵, Ignacio Sanz⁶ and Cristina Drenkard⁵, ¹Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA, ²Division of Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine, Atlanta, GA, ³Medicine, Emory University School of Medicine, atlanta, GA, ⁴Medicine, Emory University School of Medicine, Atlanta, GA, ⁵Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁶Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA
Background/Purpose: While the contribution of humoral immunity to SLE is well established, the role it plays in chronic cutaneous lupus erythematosus (CCLE) is less clear.…
Abstract Number: 1633 • 2017 ACR/ARHP Annual Meeting
Use of Emergency Department (ED) and Resulting Hospitalization By Patients with Systemic Lupus Erythematosus (SLE) in a Predominantly Afro-Caribbean Inner-City Cohort
Maushmi Savjani¹, Justin Levinson² and Ellen M. Ginzler³, ¹Internal Medicine, Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, ²Medicine, Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, ³Rheumatology, Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY
Background/Purpose: Given the complexity, chronicity and associated co-morbidities, management of SLE poses a challenge. Despite established care in private and fellow/resident clinics, our patients often…
Abstract Number: 2559 • 2017 ACR/ARHP Annual Meeting
KZR-616, a Selective Inhibitor of the Immunoproteasome, Blocks the Disease Progression in Multiple Models of Systemic Lupus Erythematosus (SLE)
Tony Muchamuel¹, Janet Anderl², R Andrea Fan², Henry W. B. Johnson³, Christopher J Kirk⁴ and Eric Lowe², ¹Pharmacology and Toxicology, Kezar Life Sciences, South San Francisco, CA, ²Biology, Kezar Life Sciences, South San Francisco, CA, ³Medicinal Chemistry, Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, South San Francisco, CA
Background/Purpose: The proteasome inhibitor bortezomib has been used successfully to treat patients with SLE. The immunoproteasome is a distinct class of proteasome found predominantly in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.